Loading the records…
Loading the records…
Leidos Holdings ($LDOS) received a $826M task order from NIH for NCI operational support, adding significant revenue to its healthcare services backlog.
Leidos' stock may see positive sentiment from this award, as it demonstrates continued demand for its services in the healthcare sector. Investors should view this as a sign of stable revenue growth from government contracts.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, was awarded a $826M delivery order by the National Institutes of Health for the NCI Operational Task Order covering FY26-FY27. This contract involves providing operational and technical support to the National Cancer Institute. Leidos Holdings ($LDOS) is the publicly traded parent company, and this award represents approximately $413M in annual revenue, or about 2.7% of its FY2025 revenue of $15.3B. While no direct legislative connection was identified among the provided bill signals, the award reflects continued government investment in healthcare research infrastructure. Subcontractors for this contract may include IT services and scientific equipment providers, but specific names are not disclosed. Historically, Leidos has consistently won large task orders from NIH, contributing to steady growth in its health and civil segment. This award reinforces Leidos' position as a key contractor for biomedical research support.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award of delivery order for NCI operational support
Who must act
National Institutes of Health (NIH) awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings
What happens
$826M added to Leidos' backlog over two years, representing approximately $413M in annual revenue, or about 2.7% of FY2025 revenue
Stock impact
Leidos will provide operational and technical support to the National Cancer Institute, strengthening its health and civil segment. This award adds to Leidos' growing healthcare portfolio and supports its revenue base.
Matched on shared policy language across AI analyses, with ticker & timing weight
LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
Executive orders & memoranda affecting the same sectors or companies
This proclamation reaffirms U.S. leadership in space exploration, declaring outer space open to development and permanent settlement by American citizens. It sets goals for a return to the Moon by 2028 and a future Mars mission, while emphasizing support for the commercial space industry. The action does not invoke specific legal authorities or direct new funding but signals continued policy focus on space.
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$825,985,691
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →